# Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
Canonical URL: https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-successful-completion-of-a-drug-drug-interaction-study-in-healthy-volunteers-supporting-nxp900-s-potential-as-a-combination-partner-with-leading-therapies
Ticker: NVCT
Company: Nuvectis Pharma
Source: Nuvectis Pharma
Published: 2025-07-08 08:00 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p> </p> <ul><li style="margin-top:6pt; margin-bottom:6pt;">Drug-drug interaction ("DDI") clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic

## Article Body
Drug-drug interaction ("DDI") clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.

The market leading epidermal growth factor receptor...
## Recent Company News
- 2025-09-04 07:30 EST — [Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-at-the-h-c-wainwright-27th-annual-global-investment-conference) — Source: Nuvectis Pharma
- 2025-08-11 16:30 EST — [Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-the-initiation-of-the-phase-1b-program-for-nxp900) — Source: Nuvectis Pharma
- 2025-08-05 07:30 EST — [Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2025-financial-results-and-business-highlights) — Source: Nuvectis Pharma
- 2025-07-31 07:45 EST — [Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-provides-final-clinical-data-update-from-the-nxp800-phase-1b-study-in-ovarian-cancer-and-reports-completion-of-the-nxp900-phase-1a-dose-escalation-study) — Source: Nuvectis Pharma
- 2025-07-08 08:00 EST — [Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-successful-completion-of-a-drug-drug-interaction-study-in-healthy-volunteers-supporting-nxp900-s-potential-as-a-combination-partner-with-leading-therapies) — Source: Nuvectis Pharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)